Pharmaceutical Report Library l Report Store l Pharma Intelligence

Bax 817

BAX 817 is an rfVIIa therapy in development by Baxalta for patients with hemophilia A or B with inhibitors. FVIIa therapy can circumvent the need for fVIII and fIX in the coagulation cascade by directly activating factor X…

March 14, 2016

Find out more

France, Musculoskeletal Market Opportunities: Disease Incidence and Prevalence, and Surgical Procedure Volumes

$1,995.00

This report presents the disease incidence and prevalence and surgical procedure volumes for selected musculoskeletal disorders and interventional procedures in France

November 1, 2012

Find out more

Reasanz

Reasanz (serelaxin; Novartis) has not yet obtained approval in the US, Japan, or EU for the treatment

of acute decompensated heart failure (ADHF), despite its fast track and breakthrough therapy

designations from the US Food and Drug Administration (FDA).

March 16, 2016

Find out more

Disease Analysis: Prostate Cancer

Prostate cancer occurs when malignant cells originate in the prostate gland. The vast majority of prostate cancers are adenocarcinomas, but other less common types include sarcomas, small cell carcinomas, neuroendocrine tumors, and transitional cell carcinomas. Some prostate cancers can grow and spread quickly, but many are relatively indolent. Because of this, depending on patient age and other co-morbidities, some prostate cancer patients may not receive active treatment for the disease during their lifetime.

March 2, 2022

Find out more

Ebola KOL Interview #3

$599.00

Ebola KOL Interview #3

December 2, 2014

Find out more

Encorafenib

Encorafenib (Array BioPharma/Pierre Fabre/Ono Pharmaceutical) is a RAF inhibitor with selective anti-proliferative and apoptotic activity in cells expressing BRAF V600E.

May 23, 2018

Find out more

Rexulti

Rexulti (brexpiprazole) is Otsuka’s latest atypical antipsychotic, approved simultaneously in the US for schizophrenia and major depressive disorder in July 2015. The drug acts similarly to Abilify (aripiprazole; Otsuka/Lundbeck), displaying partial agonism of dopamine receptors in the central nervous system.

March 29, 2019

Find out more

Respiratory Syncytial Virus (RSV) Prevention KOL Interview – US #1

$599.00

This interview with a US-based key opinion leader (KOL) provides insights into upcoming changes in treatment algorithms, trial data for late-phase pipeline prophylaxis therapies, competitive positioning, and vaccination coverage rates. Pricing and reimbursement, as well as unmet needs, are also discussed. Key pipeline assets highlighted include nirsevimab, RSVpreF, and GSK3844766A.

December 22, 2021

Find out more

U.S. Markets for Orthopedic Biomaterials for Viscosupplementation and Cartilage, Ligament/Tendon, and Meniscal Repair and Regeneration

$3,750.00

The United States (U.S.) market for orthopedic biomaterials, as covered by the scope of this report, comprises bioresorbable fixation devices, visco supplementation products, cartilage repair and regeneration technologies.

July 1, 2013

Find out more

Heart Valve Repair and Replacement Devices Market

$4,750.00

The global market for heart valve repair and replacement devices is being driven by the increasing burden of heart valve disease, which left untreated can lead to severe and life-threatening cardiovascular diseases. This analysis includes a discussion of products, current/forecast markets, competitors, and opportunities in the worldwide heart valve repair and replacement devices market, which includes percutaneous balloon valvuloplasty, heart valve surgery, transcatheter aortic valve replacement (TAVR), and transcatheter mitral valve regurgitation therapy (TMVrep). Global heart valve repair and replacement device sales are projected to expand at a compound annual growth rate (CAGR) of 10.9% during 2016-21, increasing from approximately $4,834.7m in 2016 to an estimated $8,094.4m in 2021. Countries/regions covered by this report include the US, five major European markets (France, Germany, Italy, Spain, and the UK), Japan, and the Rest of the World segment (which combines estimated sales data for all other countries).

July 1, 2017

Find out more

Gazyva

Gazyva (obinutuzumab; Roche/Biogen/Chugai/Nippon Shinyaku) is a third-generation, type II glycoengineered, humanized anti-CD20 monoclonal antibody (MAb) that recognizes the type II epitope of the CD20 antigen.

January 31, 2019

Find out more

Onglyza

Onglyza (saxagliptin; AstraZeneca/Kyowa Hakko Kirin) is a member of the dipeptidyl peptidase-IV (DPP-IV) inhibitor class. DPP-IV is an enzyme responsible for the rapid degradation of the incretin hormone glucagon-like peptide-1 (GLP-1), which is released postprandially from the gut.

November 7, 2017

Find out more

Disease Analysis: Hepatocellular Carcinoma (HCC)

Liver cancers can be differentiated based on the cell types they affect. The most common form of liver cancer is hepatocellular carcinoma (HCC), which accounts for 80–90% of liver cancer cases. HCC affects hepatocellular cells, or hepatocytes, which are the most abundant cell type in the liver and are responsible for the liver’s primary functions, such as bile production, protein synthesis, and detoxification. This differentiates HCC from other types of liver cancer such as cholangiocarcinoma, which affects the epithelial cells lining the bile ducts, and angiosarcoma, which affects the endothelial cells lining blood vessels of the liver.

May 19, 2022

Find out more

Disease Analysis: Chronic Heart Failure

Chronic heart failure (CHF) is a progressive condition in which the heart muscle is unable to pump enough blood to meet the needs of the body. CHF can result from functional abnormalities such as ventricular dysfunction or arrhythmias, or structural disorders of the myocardium or valves.

March 31, 2021

Find out more